Aesica: enabling manufacturing expansion

Aesica Pharmaceuticals manufactures active pharmaceutical ingredients.

In 2004 LDC supported an MBO of Aesica Pharmaceuticals from its parent company BASF.

Manufacturing expansion

Between 2005 and 2011, LDC provided management with financial and strategic support to implement a rapid and impressive expansion plan. This has focused on enhancing the Aesica manufacturing capabilities, developing new service lines, adding new products to its portfolio and increasing its presence in major international growth markets.

The business also acquired two UK manufacturing sites, three manufacturing sites in Germany and Italy and leading specialist R5 Pharmaceuticals.

Aesica established itself as one of the top 12 pharmaceutical contract manufacturers globally. This success is reflected in turnover growth which rose seven-fold to $180million and number of employees grew from 150 (2004) to 1,300 (2011). The company also ranked third in the Sunday Times Deloitte Buyout Track 100 in 2011, having grown every year for the previous three years.

In 2011 LDC exited Aesica to Silverfleet Capital.